New data from Zafgen's Prader-Willi study

Zafgen Inc. (NASDAQ:ZFGN) presented secondary endpoint data from the Phase III bestPWS (ZAF-311) trial evaluating subcutaneous beloranib ( ZGN-440) to treat Prader-Willi syndrome. Data were presented at the Endocrine Society meeting in Boston.

Patients receiving 1.8 mg beloranib twice weekly had a 2.9% reduction and patients receiving 2.4 mg twice weekly had a 5.7% reduction in total body mass over the six-month treatment period, vs. a 3.4% increase for placebo. Low- and high-dose beloranib decreased fat mass by 4.5% and 9.8% vs. a 5.9% increase for placebo (p<0.0001 for all). ...